Manal Hasan

تحويل الألم إلى تقدم 💪🌺

[FirstWord HealthTech @fwhealthtech]

Enveda, Anthropic take aim at drug-development bottlenecks with Claude @enveda @AnthropicAI https://t.co/kO484C6iv5

[MobiHealthNews @MobiHealthNews]

OpenAI sued over allegedly dangerous ChatGPT medication advice www.​mobihealthnews.​com/news/openai-sued-over-allegedly-dangerous-chatgpt-medication-advice

[Solve ME/CFS Initiative @PlzSolveCFS]

This November, for National Family Caregivers Month, we’re joining forces with @BatemanHorne, @OpenMedF and @MEActNet to highlight resources, events, and community support for caregivers.

Together, we’re stronger, and united in care. 💙
Follow and share using #UnitedForME

[Oncology Tube @oncologytube]

Thank you for the repost! @IrvingVF_Onco

[Brian Ahier @ahier]

Is AI Really a Black Box?

Neural Networks May Be Easier to Understand Than We Thought

by @EddyTheGent

https://t.co/slgf84aGAX

[Dr Keith Geraghty @keithgeraghty]

Nigel Speight 2017 - and this is exactly what I find researching ME and speaking to drs and nurses. So, more work is needed, more research funding, and we need to think of new ways to fund ME research, not only vital bioscience, but education of health professionals, public health and more. Otherwise, the next ME patient going to the GP or into hospital, will face the same stigma and dismissal.

[ASCP @ASCP_Chicago]

When an antibiogram shows a drop in susceptibility from one year to the next, it is natural to wonder whether resistance is on the rise. But a percentage alone does not tell the whole story. Farah Tayyab's, MLS(ASCPi), M(ASCPi), CLT(NYSED), article on Critical Values walks through the key questions to ask before drawing conclusions, and how laboratory professionals can add important context to the discussion. Read More. https://t.co/8yuNpgqKga

#StrongerTogether #LaboratoryMedicine

[Nikkei Asia @NikkeiAsia]

As AI revives magnetic tape, Fujifilm plans biggest buildup in two decades https://t.co/NWl8mxUIGO

[Oncology Tube @oncologytube]

VIDEO: HRR-mut mHSPC — Talzenna + enzalutamide now? FDA Oct 26 2026; TALAPRO-3 rPFS HR 0.48 🧬⚠️

👉 https://t.co/1U4gtxeggl

🔹 FDA approved talazoparib + enzalutamide for HRR-mutated mAPMN/S (hormone-sensitive) prostate; TALAPRO-3 n=599
🔹 Investigator rPFS median NR vs 45.8 mo, HR 0.48; FoundationOne CDx / Liquid CDx companion diagnostics
🔹 OS immature at the rPFS analysis — do not claim OS benefit; not mCRPC / not TALAPRO-2 numbers

Clinic frame: new mHSPC/mAPMN/S PARP combo in HRR-mut disease — keep prior mCRPC TALAPRO-2 OT coverage distinct.

@neerajaiims @EAntonarakis @Silke_Gillessen @DrRanaMcKay @quimmateo @OncoAlert @Ecastromarcos @Dolmos77 @PBarataMD @DrScottTagawa @AtishChoudhury @TiansterZhang @shilpaonc @Adam_Weiner535 @zklaassen_md @WallisCJD @ChapinMD @DrKarineTawagi @sonpavde @MikeSerzanMD @davidjeinstein @jgong15 @katy_beckermann @tompowles1 @PGrivasMDPhD @alantanmd @DrYukselUrun @APCCC_Lugano @cdanicas @dralvaropinto @PCaParker @montypal @DrChoueiri @hsafaMD @urogeek

#prostatecancer #pcsm #mHSPC #Talzenna #TALAPRO3 #GUonc

[Carole Bruce @CaroleBruce17]

Dr William Weir talking about #ME He doesn’t spare Simon Wessely!

Collaboration for Change" - Newry March 2026 Dr Weir https://t.co/zDpNpjzt2i via @YouTube

[Multiple Sclerosis News Today @MSNewsToday]

Get the scoop: https://t.co/V5AIkBlv5R

Early treatment with vidofludimus calcium may lead to less long-term disability in people with progressive forms of MS, data show.

#MultipleSclerosis #MS #MultipleSclerosisNewsToday #Bionews

[Sara Tolaney @stolaney1]

IT trastuzumab and pertuzumab for HER2+ LMD

(Pts could continue treatment with HER2-directed systemic therapy)

@OncoAlert #ESMO26

[The Alliance for Longevity Initiatives (A4LI) @theA4LI]

Alzheimer’s disease can begin changing the brain years before symptoms appear. Understanding what drives those changes, and intervening earlier, could open new opportunities to prevent or delay cognitive decline. @ARPA_H is investing up to $48.8 million in new Alzheimer’s research focused on that early window.

Mass General Brigham is launching a national clinical trial platform to test multiple preventive therapies simultaneously, before symptoms emerge. Washington University in St. Louis is building an open, AI-enabled data platform to help uncover the biological drivers of the disease. Other teams will investigate the earliest stages of cognitive decline and study how interventions affect brain health in at-risk older adults.

These projects build on a broader ARPA-H Alzheimer’s research portfolio totaling up to $155.3 million. It includes BIOGAMI, which aims to detect and address early protein dysfunction, and NIGHT, which is studying ways to improve sleep and mitigate women’s elevated risk of Alzheimer’s.

📖 Read more here: https://t.co/BUFmC3lwqA

At A4LI, we believe advancing human health means addressing age-related diseases before they take hold. Research that uncovers the earliest drivers of Alzheimer’s could help shift the focus from managing disease to preventing or delaying its onset, giving more people the opportunity to live longer, healthier lives.

[MobiHealthNews @MobiHealthNews]

Event: ARPA-H on how AI must solve healthcare’s bottlenecks www.​mobihealthnews.​com/news/event-arpa-h-how-ai-must-solve-healthcares-bottlenecks

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

More from #ESMO2026!

#VHIO researchers @DrCeSarcoma, @CristinaSaura3 and Claudia Valverde have been presenting their research at this year's congress in Madrid.

Great to see our teams sharing their work with the international oncology community!

[The Science of Parkinson's @ScienceofPD]

A study of chronic rotenone administration (21 days) in mice finds #Parkinsons-like behaviour after 4 weeks, but "after 12 months of toxin cessation, rotenone-treated mice exhibited behavioral performance & TH expression levels" comparable to controls
https://t.co/6JLbfvmddu

[IASLC @IASLC]

⏰ The IASLC Guidelines Survey closes today!

Help us better understand how thoracic cancer clinical guidelines are used in practice and where challenges remain.

Share your perspective: https://t.co/yQ7QbeHuqv

[ASCP @ASCP_Chicago]

The future of pathology starts with the next generation. 🔬

ASCP’s new medical student resource is designed to help students explore what a future in pathology can look like, from hands-on research and mentorship to professional development and exposure to the policy issues shaping laboratory medicine and healthcare.

Through opportunities to collaborate with experts, contribute to meaningful research, and build skills in research, analysis, communication, and policy, medical students can discover the many ways pathology makes an impact on patient care.

Explore the possibilities. Discover pathology. Help shape the future of diagnostic medicine.

🔗 https://t.co/zPlHGOkkMw

#ASCP #Pathology #MedicalStudents #MedEd #LaboratoryMedicine #FutureOfPathology

[American College of Cardiology @ACCinTouch]

A focused @MedAxiom #CVTransforum session provided a first-hand look at the infrastructure needed to define quality and continuously improve outcomes in a cardiovascular ASC. Learn how the #NCDR CV ASC Registry Suite can be part of the solution at https://t.co/LHm3VVH2TK

[NEJM @NEJM]

Matthew Vogel, MBA, discusses the emergence of clinical trial prediction markets. Listen to the full interview with NEJM Executive Managing Editor Stephen Morrissey (@srm128): https://t.co/KnAW8AJ7Qs